UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2390-2396

2013

Volltextzugriff (PDF)

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy

Clinical pharmacology and therapeutics, 2016-09, Vol.100 (3), p.212-214

2016

Volltextzugriff (PDF)

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

British journal of cancer, 2009-11, Vol.101 (9), p.1543-1548

2009

Volltextzugriff (PDF)

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Annals of oncology, 2013-09, Vol.24 (9), p.2382-2389

2013

Volltextzugriff (PDF)

Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer

Annals of oncology, 2005-07, Vol.16 (7), p.1069-1075

2005

Volltextzugriff (PDF)

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Annals of oncology, 2010-03, Vol.21 (3), p.540-547

2010

Volltextzugriff (PDF)

Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1335-1343

Socinski, M. A.

2002

Volltextzugriff (PDF)

Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.182-191

2014

Volltextzugriff (PDF)

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Annals of oncology, 2015-06, Vol.26 (6), p.1134-1142

2015

Volltextzugriff (PDF)

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

Annals of oncology, 2016-08, Vol.27 (8), p.1573-1579

2016

Volltextzugriff (PDF)

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)

Annals of oncology, 2009-06, Vol.20 (6), p.1068-1073

2009

Volltextzugriff (PDF)

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

Current oncology (Toronto), 2014-10, Vol.21 (5), p.e691-703

Socinski, M A

2014

Volltextzugriff (PDF)

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-02, Vol.24 (2), p.314-321

2013

Volltextzugriff (PDF)

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer

Annals of oncology, 2006-01, Vol.17 (1), p.104-109

2006

Volltextzugriff (PDF)

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity

Annals of oncology, 2004-07, Vol.15 (7), p.1033-1041

2004

Volltextzugriff (PDF)

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii744-viii744

2018

Volltextzugriff (PDF)

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Annals of oncology, 2018-08, Vol.29 (8), p.1701-1709

2018

Volltextzugriff (PDF)

IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii750-viii751

2018

Volltextzugriff (PDF)

Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii504-viii504

2018

Volltextzugriff (PDF)

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

Annals of oncology, 2019-04, Vol.30, p.ii48-ii49

2019

Volltextzugriff (PDF)

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

Annals of oncology, 2018-11, Vol.29, p.ix177-ix178

2018

Volltextzugriff (PDF)

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii498-viii499

2018

Volltextzugriff (PDF)

nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study

Annals of oncology, 2018-10, Vol.29, p.viii749-viii750

2018

Volltextzugriff (PDF)

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO open, 2024-04, Vol.9 (4), p.102961-102961, Article 102961

2024

Volltextzugriff (PDF)

1320_PR Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S153-S153

2016

Volltextzugriff (PDF)

1 – 25 von 420

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(405)
Mit Volltextzugriff
(384)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(166)
Science & Technology
(160)
Life Sciences & Biomedicine
(159)
Oncology
(141)
Male
(115)
Female
(111)
Lung Neoplasms - Drug Therapy
(108)
Middle Aged
(99)
Aged
(96)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(93)
Adult
(88)
Biological And Medical Sciences
(80)
Medical Sciences
(78)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(77)
Lung Neoplasms - Pathology
(75)
Carcinoma, Non-Small-Cell Lung - Pathology
(60)
Aged, 80 And Over
(52)
Neoplasm Staging
(52)
Carboplatin - Administration & Dosage
(49)
Lung Neoplasms - Mortality
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(109)
Annals Of Oncology
(58)
Journal Of Thoracic Oncology
(42)
Lung Cancer
(28)
Cancer
(16)
International Journal Of Radiation Oncology, Biology, Physics
(15)
Seminars In Oncology
(13)
Chest
(11)
Clinical Lung Cancer
(10)
The Lancet Oncology
(7)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer

Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC

Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC)

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

Suchergebnisse filtern